Clin2
NCT07193667Possibly a fitRecruiting

CAR-T therapy for autoimmune diseases

Relapsed/Refractory Autoimmune Diseases

Part of Immune system & allergy clinical trials.

This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
3 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are 18 to 65 years old.
  • You have one of these autoimmune diseases: systemic lupus erythematosus (SLE), systemic sclerosis, inflammatory myopathy, or immune thrombocytopenia (ITP).
  • Your disease has not responded to standard treatment or has come back after getting better.
  • A blood test shows your B cells have the CD19 protein (a marker on some immune cells).
  • Key organs like your bone marrow, liver, kidneys, and heart are working well enough.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07040917Not yet recruiting· Early Phase 1
CAR-T cell therapy for autoimmune diseases

This trial tests whether CAR-T cells, a type of immune cell therapy, can help people with certain autoimmune diseases. If you have lupus, scleroderma, or other listed conditions, you may be able to join and see if this treatment can calm your overactive immune system.

Beijing, Beijing Municipality
NCT06548607Recruiting· Early Phase 1
CAR-T therapy for autoimmune diseases

This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.

Bengbu, Anhui
NCT07558850Recruiting
CAR-T Cell Therapy for Treatment-Resistant Autoimmune Diseases

This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.

Nanjing, Jiangsu
NCT06661811Not yet recruiting
CAR-T cell therapy for autoimmune diseases

This trial tests whether a type of immune cell therapy called CAR-T cells can help treat autoimmune diseases. It is for people who have not tried this type of therapy before.

Beijing
NCT06983964Recruiting
CAR-T cell therapy for autoimmune diseases that haven't improved

This trial tests a personalized cell therapy (CAR-T) that targets a protein called CD19 on immune cells. It's for people with certain autoimmune diseases like lupus or scleroderma that are still active despite standard treatments. The goal is to see if this therapy can help control the disease when other options haven't worked.

Beijing, Beijing Municipality
NCT06762119Not yet recruiting· Early Phase 1
CAR-T cell therapy for autoimmune diseases

This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with certain autoimmune diseases, including lupus, scleroderma, and others. The goal is to see if the treatment can help control the disease.

Hangzhou

Hear when a new Relapsed/Refractory Autoimmune Diseases trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.